Inverse expression of caveolin-1 and EGFR in thyroid cancer patients

Human Pathology

Volumn 61, Issue , 2017, Pages 164-172

  Janković, Jelena ^a   Tatić, Svetislav ^b   Božić, Vesna ^c   Živaljević, Vladan ^a   Cvejić, Dubravka ^a   Paskaš, Svetlana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

BRAF V600E; Caveolin 1; EGFR; FNAB; Thyroid cancer

Indexed keywords

B RAF KINASE; CAVEOLIN 1; MESSENGER RNA; VASCULOTROPIN; BRAF PROTEIN, HUMAN; CAV1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE SEVERITY; FINE NEEDLE ASPIRATION BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID CANCER; TUMOR INVASION; UPREGULATION; CANCER STAGING; CHEMISTRY; DNA MUTATIONAL ANALYSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR;

BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; CAVEOLIN 1; DNA MUTATIONAL ANALYSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASM STAGING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 85012305781     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2016.10.020     Document Type: Article

References (42)

1. [1] Torre, L.A., Sauer, A.M., Chen, M.S. Jr., Kagawa-Singer, M., Jemal, A., Siegel, R.L., Cancer statistics for Asian Americans, native Hawaiians, and Pacific islanders, 2016: converging incidence in males and females. CA Cancer J Clin 66 (2016), 182–202.
2. [2] Sipos, J.A., Mazzaferri, E.L., Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22 (2010), 395–404.
3. [3] Schiff, B.A., McMurphy, A.B.., Jasser, S.A., et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10 (2004), 8594–8602.
4. [4] Yarden, Y., Pines, G., The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12 (2012), 553–563.
5. [5] Pedersen, M.W., Meltorn, M., Damstrup, L., Poulsen, H.S., The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12 (2001), 745–760.
6. [6] Gan, H.K., Cvrljevic, A.N., Johns, T.G., The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J 280 (2013), 5350–5370.
7. [7] Omidfar, K., Moinfar, Z., Sohi, A.N., et al. Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies. Immunol Invest 38 (2009), 165–180.
8. [8] Sowa, G., Caveolae, caveolins, cavins, and endothelial cell function: new insights. Front Physiol, 2, 2012, 120.
9. [9] Arpaia, E., Blaser, H., Quintela-Fandino, M., et al. The interaction between caveolin-1 and rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 31 (2012), 884–896.
10. [10] Pol, A., Luetterforst, R., Lindsay, M., Heino, S., Ikonen, E., Parton, R.G., A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol 152 (2001), 1057–1070.
11. [11] Goetz, J.G., Lajoie, P., Wiseman, S.M., Nabi, I.R., Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 27 (2008), 715–735.
12. [12] Aldred, M.A., Huang, Y., Liyanarachchi, S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22 (2004), 3531–3539.
13. [13] Ito, Y., Yoshida, H., Nakano, K., et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 86 (2002), 912–916.
14. [14] Couet, J., Sargiacomo, M., Lisanti, M.P., Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272 (1997), 30429–30438.
15. [15] Kim, Y.N., Wiepz, G.J., Guadarrama, A.G., Bertics, P.J., Epidermal growth factor–stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. J Biol Chem 275 (2000), 7481–7491.
16. [16] Schmidt-Glenewinkel, H., Reinz, E., Bulashevska, S., et al. Multiparametric image analysis reveals role of Caveolin1 in endosomal progression rather than internalization of EGFR. FEBS Lett 586 (2012), 1179–1189.
17. [17] Andrews, A.M., Rizzo, V., Microparticle-induced activation of the vascular endothelium requires caveolin-1/caveolae. PLoS One, 11, 2016, e0149272.
18. [18] Overmiller, A.M., McGuinn, K.P., Roberts, B.J., et al. C-Src/Cav1-dependent activation of the EGFR by Dsg2. Oncotarget 7 (2016), 37536–37555.
19. [19] Davies, H., Bignell, G.R., Cox, C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
20. [20] Nikiforov, Y.E., Molecular analysis of thyroid tumors. Mod Pathol 24 (2011), S34–S43.
21. [21] Pratilas, C.A., Taylor, B.S., Ye, Q., et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 106 (2009), 4519–4524.
22. [22] Nikiforova, M.N., Kimura, E.T., Gandhi, M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 (2003), 5399–5404.
23. [23] Nikiforov, Y.E., Ohori, N.P., Hodak, S.P., et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 96 (2011), 3390–3397.
24. [24] Xing, M., Alzahrani, A.S., Carson, K.A., et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309 (2013), 1493–1501.
25. [25] Xing, M., Liu, R., Liu, X., et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32 (2014), 2718–2726.
26. [26] Edge, S.B., Compton, C.C., The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17 (2010), 1471–1474.
27. [27] Basolo, F., Torregrossa, L., Giannini, R., et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95 (2010), 4197–4205.
28. [28] Sapio, M.R., Posca, D., Troncone, G., et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154 (2006), 341–348.
29. [29] Jeuken, J., Sijben, A., Alenda, C., et al. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19 (2009), 661–671.
30. [30] Fu, Y., Moore, X.L., Lee, M.K., et al. Caveolin-1 plays a critical role in the differentiation of monocytes into macrophages. Arterioscler Thromb Vasc Biol 32 (2012), e117–e125.
31. [31] Jankovic, J., Paskas, S., Marecko, I., Bozic, V., Cvejic, D., Savin, S., Caveolin-1 expression in thyroid neoplasia spectrum: comparison of two commercial antibodies. Dis Markers 33 (2012), 321–331.
32. [32] Paskas, S., Jankovic, J., Marecko, I., et al. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status. Otolaryngol Head Neck Surg 150 (2014), 201–209.
33. [33] Franco, C., Martinez, V., Allamand, J.P., et al. Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol 17 (2009), 211–215.
34. [34] Rodrigues, H.G., de Pontes, A.A., Adan, L.F., Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr J 59 (2012), 417–424.
35. [35] Trimboli, P., Guidobaldi, L., Amendola, S., et al. Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules. Endocrine 52 (2016), 39–45.
36. [36] Chen, D., Qi, W., Zhang, P., Guan, H., Wang, L., Expression of the estrogen receptor alpha, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues. Oncol Lett 10 (2015), 317–320.
37. [37] Yeh, M.W., Rougier, J.P., Park, J.W., et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 13 (2006), 1173–1183.
38. [38] Zhang, L., Zhang, Y., Mehta, A., et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget 6 (2015), 9073–9085.
39. [39] Senetta, R., Miracco, C., Lanzafame, S., et al. Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro Oncol 13 (2011), 176–183.
40. [40] Fisher, K.E., Jani, J.C., Fisher, S.B., et al. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res 185 (2013), 217–224.
41. [41] Landriscina, M., Pannone, G., Piscazzi, A., et al. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid 21 (2011), 1227–1234.
42. [42] Sharma, G.K., Dhillon, V.K., Masood, R., Maceri, D.R., Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: a pilot study. Head Neck 37 (2015), 964–969.